"HSS is the world’s leading academic medical center focused on musculoskeletal health. At its core is Hospital for Special Surgery, ranked No. 1 in orthopedics for 12 years in a row by U.S. News & World Report (2021-2022). HSS has also been among the top-ranked hospitals for both orthopedics and rheumatology for 30 consecutive years."

During the past decade, Hospital for Special Surgery, New York: Division of Rheumatology conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hospital for Special Surgery, New York: Division of Rheumatology" #1 collaborator was "Immune Tolerance Network (ITN)" with 2 trials as a collaborator, "PPD" with 1 trials as a collaborator, "Rho Federal Systems Division, Inc." with 1 trials as a collaborator and "Seagen Inc." with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Hospital for Special Surgery, New York: Division of Rheumatology" are "Diffuse Cutaneous Systemic Sclerosis" (1 trials), "Lupus Nephritis" (1 trials), "Rheumatoid Arthritis" (1 trials), "Scleroderma" (1 trials) and "dcSSc" (1 trials). Many other conditions were trialed in "Hospital for Special Surgery, New York: Division of Rheumatology" in a lesser frequency.

Most popular intervention types in "Hospital for Special Surgery, New York: Division of Rheumatology" are "Drug" (2 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo for VIB4920" (2 trials), "Brentuximab Vedotin" (1 trials), "Placebo" (1 trials), "VIB4920" (1 trials) and "VIB4920 with TNFi" (1 trials). Other intervention names were less common.

The vast majority of trials in "Hospital for Special Surgery, New York: Division of Rheumatology" are 3 trials for "All" genders.

Currently, there are NaN active trials in "Hospital for Special Surgery, New York: Division of Rheumatology". undefined are not yet recruiting, 2 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Hospital for Special Surgery, New York: Division of Rheumatology, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Hospital for Special Surgery, New York: Division of Rheumatology, 1 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".